New daily pill aims to boost growth in kids with dwarfism

NCT ID NCT07297875

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called ABSK061 in children aged 3 to 12 with achondroplasia, a common form of dwarfism. The drug is taken once daily and aims to improve growth rate. The trial will first find a safe dose, then check how well it works over a year. About 110 children will take part across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ABSK061 (a drug taken orally once daily)
What this could lead to
If successful, this could lead to a daily treatment that helps children with achondroplasia grow more than they would without treatment.
What could go wrong
This is an early-phase trial with only 110 participants, so results may not apply to all. The drug may cause side effects or fail to improve growth significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Children's Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Chengdu Women's and Children's Central Hospital

    Chengde, Sichuan, China

  • Children's Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Henan Children's Hospital, Zhengzhou Children's Hospital

    Zhengzhou, Henan, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • West China Second University Hospital, Sichuan University

    Chengdu, Sichuan, China

  • Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.